This is a Validated Antibody Database (VAD) review about human CD39, based on 35 published articles (read how Labome selects the articles), using CD39 antibody in all methods. It is aimed to help Labome visitors find the most suited CD39 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
CD39 synonym: ATPDase; CD39; NTPDase-1; SPG64

others
  • flow cytometry; human; loading ...; fig 5
 CD39 antibody (R&D Systems, clone 498403) was used in flow cytometry on human samples (fig 5). Sci Rep (2019) ncbi
BioLegend
mouse monoclonal (A1)
  • mass cytometry; human; loading ...; fig s4a
BioLegend CD39 antibody (Biolegend, 328221) was used in mass cytometry on human samples (fig s4a). Biomark Res (2022) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; 1:100; loading ...; fig e4h
BioLegend CD39 antibody (Biolegend, 328206) was used in flow cytometry on human samples at 1:100 (fig e4h). Nat Med (2021) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; loading ...; fig s9b
BioLegend CD39 antibody (Biolegend, 328226) was used in flow cytometry on human samples (fig s9b). Science (2021) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; 1:50; loading ...
BioLegend CD39 antibody (Biolegend, 328230) was used in flow cytometry on human samples at 1:50. bioRxiv (2020) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; 1:250; loading ...
BioLegend CD39 antibody (BioLegend, 328226) was used in flow cytometry on human samples at 1:250. Nature (2020) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; loading ...; fig s1a
BioLegend CD39 antibody (Biolegend, 328212) was used in flow cytometry on human samples (fig s1a). J Clin Invest (2019) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; loading ...; fig 2a
BioLegend CD39 antibody (BioLegend, 328218) was used in flow cytometry on human samples (fig 2a). Cell Rep (2018) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; loading ...; fig 1a
BioLegend CD39 antibody (Biolegend, 328202) was used in flow cytometry on human samples (fig 1a). Cell (2018) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; loading ...; fig st12
In order to identify new types of human blood dendritic cells, monocytes, and progenitors through single-cell RNA-seq, BioLegend CD39 antibody (Biolegend, A1) was used in flow cytometry on human samples (fig st12). Science (2017) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; loading ...; fig 6d
BioLegend CD39 antibody (BioLegend, A1) was used in flow cytometry on human samples (fig 6d). Cell Death Dis (2016) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; loading ...; fig s8
BioLegend CD39 antibody (BioLegend, A1) was used in flow cytometry on human samples (fig s8). Science (2016) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; loading ...; fig 3i
BioLegend CD39 antibody (BioLegend, A1) was used in flow cytometry on human samples (fig 3i). Sci Rep (2016) ncbi
mouse monoclonal (A1)
  • flow cytometry; rhesus macaque; 1:50
In order to optimize vaccination with Aventis Pasteur's canarypox vector-HIV, BioLegend CD39 antibody (BioLegend, 328214) was used in flow cytometry on rhesus macaque samples at 1:50. Nat Med (2016) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; loading ...
In order to study the pharmacologic inhibition of PI3K and MEK pathways in mixed cultures of human mononuclear cells., BioLegend CD39 antibody (BioLegend, A1) was used in flow cytometry on human samples . Am J Transplant (2016) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; loading ...; fig S2,S3
In order to look at patterns of S. Typhi-specific modulation of the homing potential of circulating Treg in patients with typhoid compared to healthy individuals, BioLegend CD39 antibody (biolegend, 328213) was used in flow cytometry on human samples (fig S2,S3). PLoS Pathog (2015) ncbi
mouse monoclonal (A1)
  • flow cytometry; human
In order to investigate the primary inflammatory and regulatory T cell responses induced by BCG vaccination in adults, BioLegend CD39 antibody (Biolegend, clone A1) was used in flow cytometry on human samples . Clin Vaccine Immunol (2015) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; tbl s1
BioLegend CD39 antibody (Biolegend, A1) was used in flow cytometry on human samples (tbl s1). PLoS ONE (2015) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; fig 1
BioLegend CD39 antibody (BioLegend, A1) was used in flow cytometry on human samples (fig 1). J Autoimmun (2015) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; loading ...; fig 1
In order to investigate the role of granzyme B in T regulatory cell resistance, BioLegend CD39 antibody (BioLegend, A1) was used in flow cytometry on human samples (fig 1). J Immunol (2015) ncbi
mouse monoclonal (A1)
  • flow cytometry; rhesus macaque
BioLegend CD39 antibody (Biolegend, A1) was used in flow cytometry on rhesus macaque samples . Clin Immunol (2014) ncbi
Invitrogen
mouse monoclonal (eBioA1 (A1))
  • flow cytometry; African green monkey; loading ...; fig s4
In order to optimize the dosing regimen of neutralizing anti-HIV-1 antibodies, Invitrogen CD39 antibody (ebioscience, eBioA1) was used in flow cytometry on African green monkey samples (fig s4). Nature (2017) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; loading ...; fig 3b
In order to examine the potential of IL-2 to enhance T regulatory cell therapy, Invitrogen CD39 antibody (eBioscience, A1) was used in flow cytometry on human samples (fig 3b). Clin Exp Immunol (2017) ncbi
mouse monoclonal (eBioA1 (A1))
  • flow cytometry; human; loading ...; fig 2e
In order to observe that the use of chimeric antigen receptor technology is a clinically applicable refinement of regulatory T cell therapy for organ transplantation, Invitrogen CD39 antibody (eBioscience, eBioA1) was used in flow cytometry on human samples (fig 2e). Am J Transplant (2017) ncbi
mouse monoclonal (eBioA1 (A1))
  • flow cytometry; human; fig 7b
Invitrogen CD39 antibody (eBioscience, 25-0399-42) was used in flow cytometry on human samples (fig 7b). Sci Rep (2016) ncbi
mouse monoclonal (eBioA1 (A1))
  • flow cytometry; mouse; fig s1
Invitrogen CD39 antibody (eBioscience, A1) was used in flow cytometry on mouse samples (fig s1). Nat Immunol (2015) ncbi
mouse monoclonal (eBioA1 (A1))
  • flow cytometry; human
Invitrogen CD39 antibody (eBioscience, eBioA1) was used in flow cytometry on human samples . Hum Immunol (2015) ncbi
mouse monoclonal (eBioA1 (A1))
  • flow cytometry; human; loading ...; fig s1b
Invitrogen CD39 antibody (eBioscience, 11-0399-42) was used in flow cytometry on human samples (fig s1b). Oncotarget (2014) ncbi
mouse monoclonal (A1)
  • flow cytometry; human; 1:10; fig s6
In order to decipher how susequent acute infection is supressed in T cell responses after exposure to subinfectious hepatitis C virus, Invitrogen CD39 antibody (Invitrogen, A1) was used in flow cytometry on human samples at 1:10 (fig s6). Nat Med (2013) ncbi
mouse monoclonal (eBioA1 (A1))
  • flow cytometry; human; fig 1
In order to study T regulatory cells in inflamed human liver samples, Invitrogen CD39 antibody (eBioscience, eBio A1) was used in flow cytometry on human samples (fig 1). J Immunol (2010) ncbi
mouse monoclonal (eBioA1 (A1))
  • flow cytometry; human; fig 3
In order to show that surface IL-17A is a marker for Th17 cells, Invitrogen CD39 antibody (eBioscience, 25-0399) was used in flow cytometry on human samples (fig 3). J Immunol (2009) ncbi
mouse monoclonal (eBioA1 (A1))
  • flow cytometry; human; fig 1
In order to investigate how anti-CD3 monoclonal antibodies alter human immune responses in type 1 diabetes, Invitrogen CD39 antibody (eBioscience, eBioA1) was used in flow cytometry on human samples (fig 1). Clin Immunol (2010) ncbi
Bio-Rad
mouse monoclonal (A1)
  • blocking or activating experiments; human; 10 ug/ml
Bio-Rad CD39 antibody (AbD serotec, A1) was used in blocking or activating experiments on human samples at 10 ug/ml. Oncoimmunology (2016) ncbi
Abcam
domestic rabbit monoclonal (EPR3678(2))
  • western blot; mouse; 1:5000; loading ...; fig 6b
Abcam CD39 antibody (Abcam, ab108248) was used in western blot on mouse samples at 1:5000 (fig 6b). PLoS ONE (2017) ncbi
BD Biosciences
mouse monoclonal (TU66)
  • flow cytometry; human; fig st1
In order to find cell-surface markers specific to human neutrophils, BD Biosciences CD39 antibody (BD, 560239) was used in flow cytometry on human samples (fig st1). Exp Cell Res (2016) ncbi
Articles Reviewed
  1. Jiang Z, Qin L, Tang Y, Liao R, Shi J, He B, et al. Human induced-T-to-natural killer cells have potent anti-tumour activities. Biomark Res. 2022;10:13 pubmed publisher
  2. Spiegel J, Patel S, Muffly L, Hossain N, Oak J, Baird J, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27:1419-1431 pubmed publisher
  3. Weber E, Parker K, Sotillo E, Lynn R, Anbunathan H, Lattin J, et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science. 2021;372: pubmed publisher
  4. Mathew D, Giles J, Baxter A, Greenplate A, Wu J, Alanio C, et al. Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions. bioRxiv. 2020;: pubmed publisher
  5. Gate D, Saligrama N, Leventhal O, Yang A, Unger M, Middeldorp J, et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease. Nature. 2020;577:399-404 pubmed publisher
  6. Muhammad F, Wang D, Montieth A, Lee S, Preble J, Foster C, et al. PD-1+ melanocortin receptor dependent-Treg cells prevent autoimmune disease. Sci Rep. 2019;9:16941 pubmed publisher
  7. Finney O, Brakke H, Rawlings Rhea S, Hicks R, Doolittle D, López M, et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest. 2019;129:2123-2132 pubmed publisher
  8. Kim C, Hu B, Jadhav R, Jin J, Zhang H, Cavanagh M, et al. Activation of miR-21-Regulated Pathways in Immune Aging Selects against Signatures Characteristic of Memory T Cells. Cell Rep. 2018;25:2148-2162.e5 pubmed publisher
  9. Olin A, Henckel E, Chen Y, Lakshmikanth T, Pou C, Mikes J, et al. Stereotypic Immune System Development in Newborn Children. Cell. 2018;174:1277-1292.e14 pubmed publisher
  10. Villani A, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017;356: pubmed publisher
  11. Villa Bellosta R, Hamczyk M, Andres V. Novel phosphate-activated macrophages prevent ectopic calcification by increasing extracellular ATP and pyrophosphate. PLoS ONE. 2017;12:e0174998 pubmed publisher
  12. Nishimura Y, Gautam R, Chun T, Sadjadpour R, Foulds K, Shingai M, et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature. 2017;543:559-563 pubmed publisher
  13. Jeffery H, Jeffery L, Lutz P, Corrigan M, Webb G, Hirschfield G, et al. Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases. Clin Exp Immunol. 2017;188:394-411 pubmed publisher
  14. Boardman D, Philippeos C, Fruhwirth G, Ibrahim M, Hannen R, Cooper D, et al. Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection. Am J Transplant. 2017;17:931-943 pubmed publisher
  15. Wei C, Mei J, Tang L, Liu Y, Li D, Li M, et al. 1-Methyl-tryptophan attenuates regulatory T cells differentiation due to the inhibition of estrogen-IDO1-MRC2 axis in endometriosis. Cell Death Dis. 2016;7:e2489 pubmed publisher
  16. Sen D, Kaminski J, Barnitz R, Kurachi M, Gerdemann U, Yates K, et al. The epigenetic landscape of T cell exhaustion. Science. 2016;354:1165-1169 pubmed
  17. Jiang J, Chen X, An H, Yang B, Zhang F, Cheng X. Enhanced immune response of MAIT cells in tuberculous pleural effusions depends on cytokine signaling. Sci Rep. 2016;6:32320 pubmed publisher
  18. Vaccari M, Gordon S, Fourati S, Schifanella L, Liyanage N, Cameron M, et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016;22:762-70 pubmed publisher
  19. Zwang N, Zhang R, Germana S, Fan M, Hastings W, Cao A, et al. Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways. Am J Transplant. 2016;16:2624-38 pubmed publisher
  20. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed publisher
  21. Thibaudin M, Chaix M, Boidot R, Végran F, Derangère V, Limagne E, et al. Human ectonucleotidase-expressing CD25high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions. Oncoimmunology. 2016;5:e1055444 pubmed
  22. Muller L, Mitsuhashi M, Simms P, Gooding W, Whiteside T. Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci Rep. 2016;6:20254 pubmed publisher
  23. McArthur M, Fresnay S, Magder L, Darton T, Jones C, Waddington C, et al. Activation of Salmonella Typhi-specific regulatory T cells in typhoid disease in a wild-type S. Typhi challenge model. PLoS Pathog. 2015;11:e1004914 pubmed publisher
  24. Boer M, Prins C, van Meijgaarden K, van Dissel J, Ottenhoff T, Joosten S. Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults. Clin Vaccine Immunol. 2015;22:778-88 pubmed publisher
  25. Weinberg A, Muresan P, Richardson K, Fenton T, Domínguez T, Bloom A, et al. Determinants of vaccine immunogenicity in HIV-infected pregnant women: analysis of B and T cell responses to pandemic H1N1 monovalent vaccine. PLoS ONE. 2015;10:e0122431 pubmed publisher
  26. Wensveen F, Jelenčić V, Valentić S, Šestan M, Wensveen T, Theurich S, et al. NK cells link obesity-induced adipose stress to inflammation and insulin resistance. Nat Immunol. 2015;16:376-85 pubmed publisher
  27. Rissiek A, Baumann I, Cuapio A, Mautner A, Kolster M, Arck P, et al. The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammation. J Autoimmun. 2015;58:12-20 pubmed publisher
  28. Bhela S, Kempsell C, Manohar M, Dominguez Villar M, Griffin R, Bhatt P, et al. Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J Immunol. 2015;194:2180-9 pubmed publisher
  29. Rueda C, Wells C, Gisslen T, Jobe A, Kallapur S, Chougnet C. Effect of chorioamnionitis on regulatory T cells in moderate/late preterm neonates. Hum Immunol. 2015;76:65-73 pubmed publisher
  30. Ye S, Li Z, Luo D, Huang B, Chen Y, Zhang X, et al. Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget. 2014;5:5439-52 pubmed
  31. Demberg T, Mohanram V, Venzon D, Robert Guroff M. Phenotypes and distribution of mucosal memory B-cell populations in the SIV/SHIV rhesus macaque model. Clin Immunol. 2014;153:264-76 pubmed publisher
  32. Park S, Veerapu N, Shin E, Biancotto A, McCoy J, Capone S, et al. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat Med. 2013;19:1638-42 pubmed publisher
  33. Oo Y, Weston C, Lalor P, Curbishley S, Withers D, Reynolds G, et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol. 2010;184:2886-98 pubmed publisher
  34. Brucklacher Waldert V, Steinbach K, Lioznov M, Kolster M, Holscher C, Tolosa E. Phenotypical characterization of human Th17 cells unambiguously identified by surface IL-17A expression. J Immunol. 2009;183:5494-501 pubmed publisher
  35. Cernea S, Herold K. Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clin Immunol. 2010;134:121-9 pubmed publisher